Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy
Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy
复制标题
DOI：
10.1093/jnci/djg043
复制
发表时间：
2003-09-17
期刊：
影响因子：
--
通讯作者：
Chen, MH
中科院分区：
文献类型：
--
作者：
D'Amico, AV;Moul, JW;Chen, MH
背景：前列腺特异性抗原（PSA）定义的复发与前列腺癌特异性死亡率之间的关系仍不清楚。因此，我们通过分析两个多机构数据库，评估了放射治疗后较短的治疗后 PSA 倍增时间 (PSA-DT) 是前列腺癌特异性死亡率的替代终点这一假设。方法：对 1988 年 1 月 1 日至 2002 年 1 月 1 日期间接受手术（5918 名男性）或放射治疗（2751 名男性）的 8669 名前列腺癌患者的基线、治疗和随访信息进行整理，研究对象为局限性或局部晚期非转移性前列腺癌。我们使用 Cox 回归分析来测试治疗后 PSA-DT 是否是独立于所接受治疗的预后因素。所有统计检验都是双面的。结果：治疗后 PSA-DT 与前列腺癌特异性死亡率和全因死亡率时间具有统计学显着相关性（所有 P-Cox
Background: The relationship between prostate-specific antigen (PSA)-defined recurrence and prostate cancer-specific mortality remains unclear. Therefore, we evaluated the hypothesis that a short post-treatment PSA doubling time (PSA-DT) after radiation therapy is a surrogate end point for prostate cancer-specific mortality by analyzing two multi-institutional databases. Methods: Baseline, treatment, and follow-up information was compiled on a cohort of 8669 patients with prostate cancer treated with surgery (5918 men) or radiation (2751 men) from January 1, 1988, through January 1, 2002, for localized or locally advanced, nonmetastatic prostate cancer. We used a Cox regression analysis to test whether the post-treatment PSA-DT was a prognostic factor that was independent of treatment received. All statistical tests were two-sided. Results: The post-treatment PSA-DT was statistically significantly associated with time to prostate cancer-specific mortality and with time to all-cause mortality (all P-Cox